US FDA Approves Novo Nordisk’s Ozempic to Cut Risk of Diabetic Kidney Disease Progression
The U.S. FDA has approved Novo Nordisk’s (NYSE: NVO) Ozempic for reducing the risk of kidney failure and disease progression, […]
Latest News on Novo Nordisk A/S (NVO) Stock
Novo’s Ozempic and Wegovy Picked for US Medicare Price Negotiations
Novo Nordisk’s (NYSE: NVO) blockbuster diabetes drug Ozempic and weight-loss treatment Wegovy are among the 15 drugs targeted for Medicare
Novo’s Ozempic and Wegovy Picked for US Medicare Price Negotiations Read More »
Novo Nordisk, Other Firms Meet Danish Prime Minister to Discuss Trump Tariff Threats
COPENHAGEN – Danish businesses are concerned about a possible trade conflict with the United States over Greenland, a major lobby
Novo Nordisk, Other Firms Meet Danish Prime Minister to Discuss Trump Tariff Threats Read More »
Retail Investors Buy the Dip in Novo After Disappointing Weight-Loss Drug Data
U.S. retail investor fund flows into Novo Nordisk (NYSE: NVO) surged 32-fold on Friday, as the Danish drugmaker’s weaker-than-expected obesity
Retail Investors Buy the Dip in Novo After Disappointing Weight-Loss Drug Data Read More »
Novo Nordisk’s Drug Trial Results Weaken Danish Currency
COPENHAGEN – The Danish crown weakened on Friday after disappointing results from a late-stage trial of a new weight-loss drug
Novo Nordisk’s Drug Trial Results Weaken Danish Currency Read More »
Novo Nordisk (NYSE: NVO) Shares Plunge After CagriSema Obesity Drug Trial Results Disappoint
LONDON/COPENHAGEN – On Friday, Novo Nordisk (NYSE: NVO) revealed disappointing results in a late-stage trial for its experimental next-generation obesity
Novo Nordisk’s Dosing in CagriSema Obesity Drug Trial Puzzles Investors
LONDON/COPENHAGEN – On Friday, Novo Nordisk (NYSE: NVO) shareholders sought to find out why such a high number of patients
Novo Nordisk’s Dosing in CagriSema Obesity Drug Trial Puzzles Investors Read More »
In Weight Loss Battle, Novo and Lilly Face Growing Offensive from Licensed Copies
SHANGHAI – As Novo Nordisk (NYSE: NVO) and Eli Lilly (NYSE: LLY) expand sales of their popular diabetes and weight-loss
In Weight Loss Battle, Novo and Lilly Face Growing Offensive from Licensed Copies Read More »
Novo Nordisk to Invest $1.2 Billion in New Rare Disease Drugs Plant in Denmark
STOCKHOLM/LONDON – Novo Nordisk (NYSE: NVO), the Danish drugmaker, will invest 8.5 billion crowns ($1.20 billion) in a new facility
Novo Nordisk to Invest $1.2 Billion in New Rare Disease Drugs Plant in Denmark Read More »
